HH
Therapeutic Areas
PeptiDream Pipeline
| Drug | Indication | Phase |
|---|---|---|
| PD-1/IL-2 | Solid Tumors | Phase 1/2 |
| PPS-001 | Undisclosed Oncology | Preclinical |
| 177Lu-PNT6555 (w/ Novartis) | Small Cell Lung Cancer (DLL3+) | Phase 1 |
Leadership Team at PeptiDream
KK
Kiichi Kubota
Founder, President, CEO, Representative Director
NO
Nobuhiko Ohno
Director, Senior Managing Executive Officer, CFO
PC
Patrick C. Reid
Director, Executive Officer (Business Development)
MK
Masayuki Kondo
Director, Executive Officer
TM
Takashi Misawa
Director, Executive Officer
YI
Yoshihiro Ishikawa
Director, Executive Officer
YO
Yoshihiko Ohtaki
Independent Outside Director
YI
Yasuhiko Iwasaki
Independent Outside Director
TO
Toshihiko Otsuka
Independent Outside Director
TY
Toru Yamaguchi
Former Executive Officer / Key Scientist